ETNB
Companies
NASDAQ
89bio Inc.
Health Care
$10.00
+$2.18 (+27.88%)
Price Chart
Overview
About ETNB
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Market Cap
$796.9M
Volume
15.9M
Avg. Volume
17.7M
P/E Ratio
-2.7090595
Dividend Yield
0.00%
Employees
57.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.07
Moderate Correlation
Volatility
High (0.79)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ETNB shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$796.9M
Volume15.9M
P/E Ratio-2.71
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025